TCGA-85-A4JC-01A-11R-A24Z-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 84
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- APICAL_SURFACE+0.360
- COAGULATION+0.320
- MYOGENESIS+0.320
- INFLAMMATORY_RESPONSE+0.310
- TNFA_SIGNALING_VIA_NFKB+0.310
- ANGIOGENESIS+0.260
- HYPOXIA+0.260
- KRAS_SIGNALING_DN+0.260
- P53_PATHWAY+0.250
Top 10 suppressed
- PROTEIN_SECRETION-0.490
- MITOTIC_SPINDLE-0.330
- G2M_CHECKPOINT-0.290
- TGF_BETA_SIGNALING-0.290
- HEME_METABOLISM-0.260
- ANDROGEN_RESPONSE-0.240
- UV_RESPONSE_DN-0.240
- E2F_TARGETS-0.210
- MYC_TARGETS_V1-0.160
- INTERFERON_GAMMA_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R24 | — | — | 0.849 |
| 2 | MNG589 | — | — | 0.787 |
| 3 | SRR12202409 | — | — | 0.781 |
| 4 | SRR1334847 | GTEX | — | 0.778 |
| 5 | TCGA-OL-A66L-01A-12R-A31O-07 | — | B | 0.777 |
| 6 | SRR1489821 | GTEX | — | 0.777 |
| 7 | TCGA-AR-A2LJ-01A-12R-A19W-07 | — | B | 0.771 |
| 8 | 9a4f9e4a-dc97-4f8d-9075-537b62fb98d3 | — | — | 0.767 |
| 9 | SJEPD001505_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.766 |
| 10 | TCGA-B6-A40B-01A-11R-A239-07 | — | B | 0.766 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.360 | Temsirolimus | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |